Adenosine in the inflamed gut: A janus faced compound

Current Medicinal Chemistry

Volumn 18, Issue 18, 2011, Pages 2791-2815

  Estrela, A B ^a   Abraham, W R ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Adenosine; Adenosine receptor (AR); Allosteric modulators; Anti inflammatory; AR agonist; AR antagonist; Colitis; Gut microbiome; Inflammatory bowel disease (IBD); Intestinal inflammation; Pro inflammatory; Structure activity relationships (SAR)

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; 4 AMINO 8 CHLORO 1 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALINE; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N (5 HYDROXYNORBORNAN 2 YL) 8 (N ISOPROPYL N METHYLAMINO) 9 METHYLADENINE; 6 N CYCLOHEXYL 2' O METHYLADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; APADENOSON; ATL 202; GASTROINTESTINAL AGENT; GW 493838; INO 8875; LUF 5735; NAXIFYLLINE; NNC 21 0136; REGADENOSON; RG 14202; ROLOFYLLINE; SELODENOSON; TECADENOSON; UK 432097; UNCLASSIFIED DRUG; UNINDEXED DRUG; VUF 5472;

ALLOSTERISM; ARTICLE; DIGESTIVE SYSTEM INFLAMMATION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE INFECTION; NONHUMAN; NUCLEIC ACID METABOLISM; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ADENOSINE; ADRENERGIC AGONISTS; ADRENERGIC ANTAGONISTS; ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79959345383     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796011274     Document Type: Article

References (284)

1. Newby, A. C. Adenosine and the concept of retaliatory metabolites. Trends Biochem. Sci., 1984, 9, 42-44.
2. Haskó, G.; Cronstein, B. N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol, 2004, 25(1), 33-39. (Pubitemid 38032805)
3. Löffler, M.; Morote-Garcia, J. C.; Eltzschig, S. A.; Coe, I. R.; Eltzschig, H. K. Physiological roles of vascular nucleoside transporters. Arterioscler. Thromb. Vasc. Biol., 2007, 27(5), 1004-1013. (Pubitemid 46641985)
4. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacol. Rev., 2001, 53, 527-552. (Pubitemid 33136237)
5. Jacobson, K. A.; Gao, Z. G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov, 2006, 5(3), 247-264. (Pubitemid 43336037)
6. 3 gene products, oxidative stress, and immune modulation. Biochem. Pharmacol, 2003, 65(9), 1529-1538. (Pubitemid 36555840)
7. 2B) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis. Cell. Mol. Life Sci., 2005, 62, 2647-2657. (Pubitemid 41721236)
8. Fortin, A.; Harbour, D.; Fernandes, M.; Borgeat, P.; Bourgoin, S. Differential expression of adenosine receptors in human neutrophils: up-regulation by specific Th1 cytokines and lipopolysaccharide. J. Leukoc. Biol, 2006, 79, 574-585. (Pubitemid 44831234)
9. 2B adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J. Biol. Chem., 1995, 270(5), 2387-2394.
10. Gessi, S.; Varani, K.; Merighi, S.; Ongini, E.; Borea, P. A. A2a adenosine receptors in human peripheral blood cells. Br. J. Pharmacol, 2000, 129, 2-11. (Pubitemid 30072665)
11. Panther, E.; Idzko, M.; Herouy, Y.; Rheinen, H.; Gebicke-Haerter, P. J.; Mrowietz, U.; Dichmann, S.; Norgauer, J. Expression and function of adenosine receptors in human dendritic cells. FASEB J., 2001, 15, 1963-1970. (Pubitemid 32848800)
12. Koshiba, M.; Kojima, H.; Huang, S.; Apasov, S.; Sitkovsky, M. V. Memory of extracellular adenosine A2a purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem., 1997, 272, 25881-25889. (Pubitemid 27438913)
13. Deaglio, S.; Dwyer, K. M.; Gao, W.; Friedman, D.; Usheva, A.; Erat, A.; Chen, J. F.; Enjyoji, K.; Linden, J.; Oukka, M.; Kuchroo, V. K.; Strom, T. B.; Robson, S. C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med., 2007, 204(6), 1257-1265. (Pubitemid 46919862)
14. Fredholm, B. B.; Irenius, E.; Kull, B.; Schulte, G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol, 2001, 61(4), 443-448. (Pubitemid 32168226)
15. Cronstein, B. N.; Daguma, L.; Nichols, D.; Hutchison, A. J.; Williams, M. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J. Clin. Invest, 1990, 85(4), 1150-1157. (Pubitemid 20123757)
16. 2 receptors. J. Immunol, 1992, 148(7), 2201-2206.
17. Takahashi, H. K.; Iwagaki, H.; Hamano, R.; Wake, H.; Kanke, T.; Liu, K.; Yoshino, T.; Tanaka, N.; Nishibori, M. Effects of adenosine on adhesion molecule expression and cytokine production in human PBMC depend on the receptor subtype activated. Br. J. Pharmacol, 2007, 150(6), 816-822. (Pubitemid 46440211)
18. Yang, A.; Mucsi, A. D.; Desrosiers, M. D.; Chen, J. F.; Schnermann, J. B.; Blackburn M. R.; Shi, Y. Adenosine mediated desensitization of cAMP signaling enhances T-cell responses. Eur J Immunol, 2010, 40(2), 449-459.
19. Flach, T. L.; Pang, W.; Chau, E. M. T.; Desrosiers, M. D.; Shi, Y. Adenosine primes resting stage dendritic cells before their activation. Biochem. Biophys. Res. Commun., 2009, 380, 748-751.
20. Ohta, A.; Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature, 2001, 414(6866), 916-920. (Pubitemid 34024743)
21. 2A receptor-dependent and independent mechanisms. FASEB J., 2000, 14(13), 2065-2074.
22. 3 adenosine receptor. J. Pharmacol. Exp. Ther., 2006, 317(1), 172-180.
23. 3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J. Pharmacol. Exp. Ther., 2006, 316(1), 71-78. (Pubitemid 41832582)
24. 2A receptors inhibits IL-12 production by human monocytes. J. Immunol., 2000, 164(1), 436-442. (Pubitemid 30013019)
25. 2B receptor-mediated posttranscriptional mechanism. J. Immunol., 2005, 175(12), 8260-8270. (Pubitemid 41798391)
26. Jijon, H. B.; Walker, J.; Hoentjen, F.; Diaz, H.; Ewaschuk, J.; Jobin, C.; Madsen, K. L. Adenosine is a negative regulator of NF-kB and MAPK signaling in human intestinal epithelial cells. Cell. Immunol., 2005, 237, 86-95. (Pubitemid 43117204)
27. Eltzschig, H. K.; Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med., 2011, 364(7), 656-665.
28. Eltzschig, H. K.; Abdulla, P.; Hoffman, E.; Hamilton, K. E.; Daniels, D.; Schönfeld, C.; Löffler, M.; Reyes, G.; Duszenko, M.; Karhausen, J.; Robinson, A.; Westerman, K. A.; Coe, I. R.; Colgan, S. P. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med., 2005, 202(11), 1493-1505. (Pubitemid 41746596)
29. Morote-Garcia, J. C.; Rosenberger, P.; Nivillac, N. M.; Coe, I. R.; Eltzschig, H. K. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterol., 2009, 136(2), 607-618.
30. Synnestvedt, K.; Furuta, G. T.; Comerford, K. M.; Louis, N.; Karhausen, J.; Eltzschig, H. K.; Hansen, K. R.; Thompson, L. F.; Colgan, S. P. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest., 2002, 110(7), 993-1002.
31. Eltzschig, H. K.; Ibla, J. C.; Furuta, G. T.; Leonard, M. O.; Jacobson, K. A.; Enjyoji, K.; Robson, S. C.; Colgan, S. P. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J. Exp. Med., 2003, 198(5), 783-796. (Pubitemid 37087777)
32. Karhausen, J.; Furuta, G. T.; Tomaszewski, J. E.; Johnson, R. S.; Colgan, S. P.; Haase, V. H. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest., 2004, 114(8), 1098-1106. (Pubitemid 39578699)
33. Rosenberger, P.; Schwab, J. M.; Mirakaj, V.; Masekowsky, E.; Mager, A.; Morote-Garcia, J. C.; Unertl, K.; Eltzschig, H. K. Hypoxia-inducible factordependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat. Immunol., 2009, 10(2), 195-202.
34. 2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J. Immunol., 2005, 174(2), 1073-1080. (Pubitemid 40094304)
35. 2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J. Immunol., 2009, 182(8), 4616-4623.
36. Desrosiers, M. D.; Cembrola, K. M.; Fakir, M. J.; Stephens, L. A.; Jama, F. M.; Shameli, A.; Mehal, W. Z.; Santamaria, P.; Shi, Y. Adenosine deamination sustains dendritic cell activation in inflammation. J. Immunol., 2007, 179(3), 1884-1892.
37. Kobie, J. J.; Shah, P. R.; Yang, L.; Rebhahn, J. A.; Fowell, D. J.; Mosmann, T. R. Tregulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J. Immunol., 2006, 177(10), 6780-6786. (Pubitemid 44715042)
38. Nakav, S.; Chaimovitz, C.; Sufaro, Y.; Lewis, E. C.; Shaked, G.; Czeiger, D.; Zlotnik, M.; Douvdevani, A. Anti-inflammatory preconditioning by agonists of adenosine A1 receptor. PLoS One, 2008, 3(5), e2107.
39. Smith, S. R.; Denhardt, G.; Terminelli, C. A role for histamine in cytokine modulation by the adenosine A (3) receptor agonist, 2-Cl-IB-MECA. Eur. J. Pharmacol., 2002, 457(1), 57-69. (Pubitemid 35379976)
40. Sitaraman, S. V.; Merlin, D.; Wang, L.; Wong, M.; Gewirtz, A. T.; Si-Tahar, M.; Madara, J. L. Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6. J. Clin. Invest., 2001, 107, 861-869. (Pubitemid 32274039)
41. 2B receptor stimulation in U373 MG cells depends on p38 mitogen activated kinase and protein kinase C. Neurochem. Int., 2005, 46(6), 501-512. (Pubitemid 40349598)
42. 2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J. Pharmacol. Exp. Ther., 2008, 324(2), 694-700. (Pubitemid 351185857)
43. 2B adenosine receptor gene ablation on proinflammatory adenosine signaling in mast cells. J. Immunol., 2008, 180(11), 7212-7220.
44. Jackson, J. R.; Seed, M. P.; Kircher, C.; Willoughby, D. A.; Winkler, J. D. The codependence of angiogenesis and chronic inflammation. FASEB J., 1997, 11, 457-465. (Pubitemid 27259987)
45. 3 adenosine receptors. Circ. Res., 2003, 92(5), 485-492. (Pubitemid 36368660)
46. Novitskiy, S. V.; Ryzhov, S.; Zaynagetdinov, R.; Goldstein, A. E.; Huang, Y.; Tikhomirov, O. Y.; Blackburn, M. R.; Biaggioni, I.; Carbone, D. P.; Feoktistov, I.; Dikov, M. M. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood, 2008, 112(5), 1822-1831.
47. 3 receptors in the human enteric nervous system. J. Comp. Neurol., 2001, 439(1), 46-64.
48. De Man, J. G.; Seerden, T. C.; De Winter, B. Y.; Van Marck, E. A.; Herman, A. G.; Pelckmans, P. A. Alteration of the purinergic modulation of enteric neurotransmission in the mouse ileum during chronic intestinal inflammation. Br. J. Pharmacol., 2003, 139(1), 172-184. (Pubitemid 36645321)
49. 2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. Eur. J. Pharmacol., 2011, 650(2-3), 639-649.
50. Fornai, M.; Antonioli, L.; Colucci, R.; Ghisu, N.; Buccianti, P.; Marioni, A.; Chiarugi, M.; Tuccori, M.; Blandizzi, C.; Del Tacca, M. A1 and A2a receptors mediate inhibitory effects of adenosine on the motor activity of human colon. Neurogastroenterol. Motil., 2009, 21 (4): 451-466.
51. 3 receptors inhibits the enteric short interplexus neural circuit triggered by histamine. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 297(6), G1147-1162.
52. Ren, T.; Grants, I.; Alhaj, M.; McKiernan, M.; Jacobson, M.; Hassanain, H. H.; Frankel, W.; Wunderlich, J.; Christofi, F. L. Impact of disrupting adenosine A (3) receptors (A (3) (-/-) AR) on colonic motility or progression of colitis in the mouse. Inflamm. Bowel. Dis., 2010 [Epub ahead of print]
53. 2B receptors (A (2B) AR) on enteric neurons regulate murine distal colonic motility. FASEB J., 2009, 23(8), 2727-2734.
54. Haskó, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov., 2008, 7(9), 759-770.
55. Palmer, T. M.; Trevethick, M. A. Suppression of inflammatory and immune responses by the A (2A) adenosine receptor: an introduction. Br. J. Pharmacol., 2008, 153 Suppl 1, S27-34. (Pubitemid 351340988)
56. Haskó, G.; Csóka, B.; Németh, Z. H.; Vizi, E. S.; Pacher, P. A (2B) adenosine receptors in immunity and inflammation. Trends Immunol., 2009, 30(6), 263-270.
57. Kolachala, V. L.; Bajaj, R.; Chalasani, M.; Sitaraman, S. V. Purinergic receptors in gastrointestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294(2), G401-410. (Pubitemid 351255513)
58. Baraldi, P. G.; Tabrizi, M. A.; Gessi, S.; Borea, P. A. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem. Rev., 2008, 108(1), 238-263. (Pubitemid 351176408)
59. Gonzólez, M. P.; Terón, C.; Teijeira, M. Search for new antagonist ligands for adenosine receptors from QSAR - Point of view. How close are we? Med. Res. Rev., 2008, 28, 329-371. (Pubitemid 351590539)
60. Nell, P. G.; Albrecht-Küpper, B. The adenosine A1 receptor and its ligands. Prog. Med. Chem., 2009, 47, 163-201.
61. Trivedi, B. K.; Bridges, A. J.; Patt, W. C.; Priebe, S. R.; Bruns, R. F. N6-Bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor. J. Med. Chem., 1989, 32, 8-11. (Pubitemid 19025277)
62. Jacobson, K. A.; Kirk, K. L.; Padgett, W. L.; Daly, J. W. Functionalized congeners of adenosine: preparation of analogs with high affinity for A1-adenosine receptors. J. Med. Chem., 1985, 28(9), 1341-1346. (Pubitemid 16252441)
63. Cheung, J. W.; Lerman, B. B. CVT-510: a selective A1 adenosine receptor agonist. Cardiovasc. Drug Rev., 2003, 21(4), 277-292. (Pubitemid 38029964)
64. Ozacmak, V. H.; Sayan, H. Pretreatment with adenosine and adenosine A1 receptor agonist protects against intestinal ischemia-reperfusion injury in rat. World J. Gastroenterol., 2007, 13(4), 538-547. (Pubitemid 46210920)
65. Knutsen, L. J.; Lau, J.; Petersen, H.; Thomsen, C.; Weis, J. U.; Shalmi, M.; Judge, M. E.; Hansen, A. J.; Sheardown, M. J. N-substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects. J. Med. Chem., 1999, 42, 3463-3477. (Pubitemid 29445081)
66. 1 receptor. J. Med. Chem., 2003, 46(8), 1492-1503. (Pubitemid 36512712)
67. Venitz, J.; Men, A. Y.; Townsend, R. W.; Dessimoz, M. Dose-dependent pharmacokinetics (PK) of short IV infusions of selodenoson (DTI-0009), a novel adenosine (A1) receptor agonist, in healthy subjects. Dose-dependent pharmacokinetics (PK) of short IV infusions of selodenoson (DTI-0009), a novel adenosine (A1) receptor agonist, in healthy subjects. Clin. Pharmacol. Ther., 2004, 75, P28.
68. Clark, K. L.; Merkel, L.; Zannikos, P.; Kelley, M. F.; Boutouyrie, B.; Perrone, M. H. AMP 579, a novel adenosine agonist for the treatment of acute myocardial infarction. Cardiovasc. Drug Rev., 2000, 18, 183-210.
69. Wagner, H.; Milavec-Krizman, M.; Gadient, F.; Menninger, K.; Schoeffter, P.; Tapparelli, C.; Pfannkuche, H.-J.; Fozard, J. R. General pharmacology of SDZ WAG-994, a potent selective and orally-activeadenosine A1 receptor agonist. Drug Dev. Res., 1995, 34, 276-288.
70. Zambrowicz, B. P.; Turner, C. A.; Sands, A. T. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr. Opin. Pharmacol, 2003, 3, 563-570. (Pubitemid 37221139)
71. 11th World Congress Pain, August 21-26, Sydney, 2005, Abstr. 637-P243. in: Nell, P. G.; Albrecht-Küpper, B. The adenosine A1 receptor and its ligands. Prog. Med. Chem., 2009, 47, 163-201.
72. Jagtap, P.; Abo, C.; Salzman, A. L. Purine derivatives as adenoseine A1 receptor agonists and methods of use thereof. WO patent 2005/117, 910, December, 15, 2005.
73. Lee, K.; Ravi, G.; Ji, X.-D.; Marquez, V. E.; Jacobson, K. A. Ring-constrained (N)-methanocarba nucleosides as adenosine receptor agonists: Independent 5'-uronamide and 2'-deoxy modifications. Bioorg. Med. Chem. Lett., 2001, 11, 1333-1337. (Pubitemid 32434364)
74. Martin, P. L.; Wysocki, R. J. Jr.; Barrett, R. J.; May, J. M.; Linden, J. Characterization of 8-(N-methylisopropyl) amino-N 6-(5'- endohydroxyendonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J. Pharmacol. Exp. Ther, 1996, 276, 490-499. (Pubitemid 126660485)
75. Müller, C. E.; Geis, U.; Grahner, B.; Lanzner, W.; Eger, K. Chiral pyrrolo[2, 3-d]pyrimidine and pyrimido[4, 5-b]indole derivatives: Structureactivity relationships of potent, highly stereoselective A1-adenosine receptor antagonists. J. Med. Chem., 1996, 39, 2482-2491.
76. Van Muijlwijk-Koezen, J. E.; Timmerman, E.; Vollinga, R. C.; Von Frijtag Drabbe Künzel, J. K.; De Groote, M.; Visser, S.; IJzerman, A. P. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J. Med. Chem., 2001, 44, 749-762. (Pubitemid 32171671)
77. Kuroda, S.; Takamura, F.; Tenda, Y.; Itani, H.; Tomisha, Y.; Akahane, A.; Sakane, K. Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. Chem. Pharm. Bull., 2001, 49, 988-998. (Pubitemid 32737603)
78. Chang, L. C. W.; Spanjersberg, R. F.; Von Frijtag Drabbe Künzel, J. K.; Mulder-Krieger, T.; van den Hout, G.; Beukers, M. W.; Brussee, J.; IJzerman, A. P. 2, 4, 6-Trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J. Med. Chem., 2004, 47, 6529-6540. (Pubitemid 39657315)
79. Akahane, A.; Katayama, H.; Mitsunaga, T.; Kita, Y.; Kusunoki, T.; Terai, T.; Yoshida, K.; Shiokawa, Y. Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist. Bioorg. Med. Chem. Lett, 1996, 6, 2059-2062. (Pubitemid 26279987)
80. 1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephroctomy without affecting blood pressure. Br. J. Pharmacol., 2007, 151, 1025-1032. (Pubitemid 47195534)
81. Lohse, M. J.; Klotz, K. N.; Lindenborn-Fotinos, J.; Reddington, M.; Schwabe, U.; Olsson, R. A. 8-Cyclopentyl-1, 3-dipropylxanthine (DPCPX) - a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol., 1987, 336, 204-210. (Pubitemid 17146111)
82. Kadowaki, M.; Tokita, K.; Nagakura, Y.; Takeda, M.; Hanaoka, K.; Tomoi, M. Adenosine A1 receptor blockade reverses dysmotility induced by ischemia-reperfusion in rat colon. Eur. J. Pharmacol, 2000, 409(3), 319-323.
83. Shimada, J.; Suzuki, F.; Nonaka, H.; Ishii, A. 8-Polycycloalkyl-1, 3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors. J. Med. Chem., 1992, 35, 924-930.
84. Pfister, J. R.; Belardinelli, L.; Lee, G.; Lum, R. T.; Milner, P.; Stanley, W. C.; Linden, J.; Baker, S. P.; Schreiner, G. Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1, 3-Dipropyl-8-[2-(5, 6-epoxy) norbornyl]xanthine. J. Med. Chem., 1997, 40, 1773-1778. (Pubitemid 27251266)
85. Naganuma, M.; Wiznerowicz, E. B.; Lappas, C. M.; Linden, J.; Worthington, M. T.; Ernst, P. B. Cutting edge: Critical role for A2a adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol, 2006, 177, 2765-2769. (Pubitemid 44277790)
86. Hutchison, A. J.; Webb, R. L.; Oei, H. H.; Ghai, G. R.; Zimmerman, M. B.; Williams, M. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther., 1989, 251(1), 47-55. (Pubitemid 19261944)
87. 2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood, 2005, 105(12), 4707-4714. (Pubitemid 40807293)
88. 2A receptor agonist CGS 21680 fails to ameliorate the course of dextran sulphate-induced colitis in mice. Inflamm. Res., 2007, 56(5), 204-209. (Pubitemid 46985835)
89. 2B receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. Inflamm. Bowel Dis., 2006, 12(2), 117-122.
90. Michael, S.; Warstat, C.; Michel, F.; Yan, L.; Müller, C. E.; Nieber, K. Adenosine A (2A) agonist and A (2B) antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation. Purinergic Signal., 2010, 6(1), 117-124.
91. Barrington, W. W.; Jacobson, K. A.; Williams, M.; Hutchison, A. J.; Stiles, G. L. Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc. Natl. Acad. Sci. USA, 1989, 86, 6572-6576. (Pubitemid 19236319)
92. Sullivan, G. W.; Rieger, J. M.; Scheld, W. M.; Macdonald, T. L.; Linden, J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A (2A) receptor agonists. Br. J. Pharmacol., 2001, 132(5), 1017-1026. (Pubitemid 32238907)
93. 2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology., 2005, 129(1), 26-33. (Pubitemid 41002039)
94. 2A Adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J. Immunol., 2005, 174, 5040-5046.
95. 2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect. Immun., 2006, 74(5), 2606-2612. (Pubitemid 43672968)
96. 3 adenosine receptors, Biochem. Pharmacol., 2003, 65, 1675-1684. (Pubitemid 36577280)
97. 2A adenosine receptor. Science, 2011, 332, 322-327.
98. Collingwood, S.; Lock, R.; Searcey, M. Optimizing drugs for local delivery. Drug News Persp., 2009, 22(10), 627-634.
99. 3 receptor antagonist activity. Eur. J. Pharmacol. 2007, 564, 219-225. (Pubitemid 46950873)
100. Matsuda, A.; Shinozaki, M.; Yamaguki, T.; Homma, H.; Nomoto, R.; Miyasaka, T.; Watanabe, Y.; Abiru, T. Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects. J. Med. Chem., 1992, 35, 241-252.
101. 2A receptor. Bioorg. Med. Chem. Lett., 2002, 12, 2935-2939. (Pubitemid 35266763)
102. Pelleg, A.; Belardinelli, L. The first second-generation adenosine drug enters the US Market. Purinergic Signal., 2008, 4, 407-408.
103. Ribeiro, J. A.; Sebastião, A. M. Caffeine and adenosine. J. Alzheimer Dis., 2010, 20, S3-S15.
104. 2A receptors: A new strategy for basal ganglia disorders. Recent Pat. CNS Drug Disc., 2007, 2, 1-21. (Pubitemid 46729088)
105. 2 antagonists. J. Med. Chem., 1992, 35, 2342-2345.
106. Moro, S.; Gao, Z. G.; Jacobson, K. A.; Spalluto, G. Progress in pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev., 2006, 26, 131-159. (Pubitemid 43334639)
107. 2A receptor antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol., 2007, 375, 133-144. (Pubitemid 46425343)
108. 2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett., 1994, 4, 2539-2544. (Pubitemid 24342941)
109. Todde, S.; Moresco, R. M.; Simonelli, P.; Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Varani, K.; Monopoli, A.; Matarrese, M.; Carpinelli, A.; Magni, F.; Kienle, M. G.; Fazio, F. Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A (2A) receptor system using positron emission tomography. J. Med. Chem., 2000, 43(23), 4359-4362. (Pubitemid 32046859)
110. 2A adenosine receptor antagonists. J. Med. Chem., 1998, 41, 2126-2133. (Pubitemid 28308630)
111. 3 adenosine receptor antagonists. Eur. J. Med. Chem., 2003, 38, 367-382. (Pubitemid 36581870)
112. Palmer, T. M.; Poucher, S. M.; Jacobson, K. A.; Stiles, G. L. 125I-4-(2-[7-amino-2-[2-furyl][1, 2, 4]triazolo[2, 3-a][1, 3, 5] triazin-5-ylamino]ethyl) phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol. Pharmacol., 1995, 48(6), 970-974.
113. 2A selective adenosine receptor antagonist. Brit. J. Pharmacol., 1995, 115, 1096-1102.
114. 2A receptor antagonists for the treatment of Parkinson's disease. Neurology, 2003, 61(Suppl. 6), S101-S106. (Pubitemid 37505558)
115. Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.; Hyun, J. L.; Stone, G. A.; Desai, M.; Williams, M. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J. Med. Chem., 1988, 31, 1014-1020.
116. Sarges, R.; Howard, H. R.; Brown, R. G.; Lebel, L. A.; Seymour, P. A.; Koe, B. K. 4-Amino[1, 2, 4]triazolo[4, 3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J. Med. Chem., 1990, 33, 2240-2254. (Pubitemid 20236673)
117. 2A receptor antagonists: comparison of three core heterocycles. Bioorg. Med. Chem. Lett., 2004, 14, 4831-4834. (Pubitemid 39165576)
118. Vu, C. B.; Shields, P.; Peng, B.; Kumaravel, G.; Jin, X.; Phadke, D.; Wang, J.; Engber, T.; Ayyub, E.; Petter, R. C. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14, 4835-4838. (Pubitemid 39165577)
119. 2A receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 4809-4813. (Pubitemid 41354811)
120. 2A antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 1333-1336. (Pubitemid 40268986)
121. Neustadt, B. R.; Hao, J.; Lindo, N.; Greenlee, W. J.; Stamford, A. W.; Tulshian, D.; Ongini, E.; Hunter, J.; Monopoli, A.; Bertorelli, R.; Foster, C.;
122. 2A receptor antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 1214-1218.
123. 2A- selective adenosine receptor antagonists. J. Med. Chem., 2000, 43, 440-448. (Pubitemid 30102084)
124. 2A receptor antagonist MSX-2. Molecules, 2008, 13, 348-359.
125. 2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J. Med. Chem., 2005, 48(22), 6887-6896. (Pubitemid 41533110)
126. Black, K. J.; Koller, J. M.; Campbell, M. C.; Gusnard, D. A.; Bandak, S. I. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J. Neurosci., 2010, 30(48), 16284-16292.
127. Baraldi, P. G.; Tabrizi, M. A.; Fruttarolo, F.; Romagnoli, R.; Preti, D. Recent improvements in the development of A (2B) adenosine receptor agonists. Purinergic Signal., 2009, 5(1), 3-19.
128. 2B Receptor ligands: Past, present and future trends. Curr. Topics Med. Chem., 2010, 10, 923-940.
129. 2B receptor ligands. Med. Res. Rev., 2006, 26, 667-698. (Pubitemid 44230416)
130. 2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J. Med. Chem., 2004, 47, 3707-3709. (Pubitemid 38900337)
131. Rosentreter, U.; Henning, R.; Bauser, M.; Krämer, T.; Vaupel, A.; Hübsch, W.; Dembowsky, K.; Salcher-Schraufstätter, O.; Stasch, J.-P.; Krahn, T.; Perzborn, E. Substituted 2-thio-3, 5-dicyano-4-aryl-6-aminopyridines and the use thereof. WO Patent 2, 001, 025, 210, April 12, 2001
132. 2B Adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J. Immunol., 2009, 182(7), 3965-3968.
133. Baraldi, P. G.; Preti, D.; Tabrizi, M. A.; Fruttarolo, F.; Saponaro, G.; Baraldi, S.; Romagnoli, R.; Moorman, A. R.; Gessi, S.; Varani, K.; Borea, P. A. N (6) - [(hetero) aryl/(cyclo) alkyl-carbamoylmethoxy-phenyl]-(2-chloro)-5'-N- ethylcarboxamido-adenosines: the first example of adenosine-related structures with potent agonist activity at the human A (2B) adenosine receptor. Bioorg. Med. Chem., 2007, 15(7), 2514-2527. (Pubitemid 46367714)
134. 2B receptors. Biochem. Pharmacol., 2004, 68, 305-312. (Pubitemid 38757699)
135. 2B adenosine receptors. Biochem. Pharmacol., 2001, 61, 657-663. (Pubitemid 32239418)
136. 2B adenosine receptors. J. Med. Chem, 2000, 43, 1165-1172. (Pubitemid 30173742)
137. 2B Adenosine Receptor Blockade Enhances Macrophage-Mediated Bacterial Phagocytosis and Improves Polymicrobial Sepsis Survival in Mice. J. Immunol., 2011, 186(4), 2444-2453.
138. 2B adenosine receptor antagonists. J. Med. Chem., 2004, 47(6), 1434-1447. (Pubitemid 38327470)
139. 2B adenosine receptors. Bioorg. Med. Chem. Lett., 2004, 14(13), 3607-3610. (Pubitemid 38737177)
140. 2B adenosine receptors. US Patent Appl., 2007, A1/20070072843.
141. 2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J. Med. Chem., 2009, 52(13), 3994-4006.
142. Thompson, R. D.; Wang, G.; Beauglehole, A.; Schmidtmann, F. Substituted 8-[6-amino-3-pyridyl]xanthines. US Patent 7, 875, 608 B2 Jan 25, 2011.
143. 2B receptors ameliorates murine colitis. Br. J. Pharmacol., 2008, 155, 127-137.
144. 2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology., 2008, 135(3), 861-870.
145. Müller, C. E.; Shi, D.; Manning, M. Jr.; Daly, J. W. Synthesis of paraxanthine analogs (1, 7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. J. Med. Chem., 1993, 36(22), 3341-3349. (Pubitemid 23335698)
146. 2B receptors to inflammatory parameters of experimental colitis. J. Immunol., 2009, 182, 4957-4964.
147. Ham, M.; Mizumori, M.; Watanabe, C.; Wang, J. H.; Inoue, T.; Nakano, T.; Guth, P. H.; Engel, E.; Kaunitz, J. D.; Akiba, Y. Endogenous luminal surface adenosine signaling regulates duodenal bicarbonate secretion in rats. J. Pharmacol. Exp. Ther., 2010, 335(3), 607-613.
148. 2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Invest., 2006, 116(8), 2173-2182. (Pubitemid 44162326)
149. 2B adenosine receptor antagonist. J. Med. Chem., 2007, 50(11), 2732-2736. (Pubitemid 46896081)
150. 2B adenosine receptor antagonists. Bioorg. Med. Chem. Lett, 2006, 16(2), 302-306. (Pubitemid 41680618)
151. 2B adenosine receptor antagonists: N-1 mono substituted 8-(pyrazol-4-yl) xanthines. Bioorg. Med. Chem. Lett., 2008, 18, 1397-1401. (Pubitemid 351226534)
152. 3 selective adenosine agonists. J. Med. Chem., 1994, 37, 636-646. (Pubitemid 24102184)
153. 6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur. J. Pharmacol., 2003, 466, 323-329. (Pubitemid 36412095)
154. Guzman, J.; Yu, J. G.; Suntres, Z.; Bozarov, A.; Cooke, H.; Javed, N.; Auer, H.; Palatini, J.; Hassanain, H. H.; Cardounel, A. J.; Javed, A.; Grants, I.; Wunderlich, J. E.; Christofi, F. L. ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflamm. Bowel Dis., 2006, 12(8), 766-789. (Pubitemid 44253762)
155. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci., 1994, 15, 298-306.
156. 3 adenosine receptor. J. Med. Chem., 2003, 46, 3775-3777. (Pubitemid 37034129)
157. 3 receptor. J. Med. Chem., 2003, 46, 353-355. (Pubitemid 36139786)
158. 3 receptors reduce ischemic myocardial injury. Am. J. Physiol Heart Circ. Physiol, 2003, 285(6), H2780-2787. (Pubitemid 37443099)
159. 3 receptor-selective agonists. Bioorg. Med. Chem. Lett., 2008, 18(9), 2813-2819. (Pubitemid 351608886)
160. 3 adenosine receptor agonists. J. Med. Chem., 2005, 48, 1745-1758. (Pubitemid 40396308)
161. 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant induced arthritis rats. Biochem. Pharmacol, 2008, 76(4), 482-494.
162. 3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg, Med. Chem., 2008, 16(18), 8546-8556.
163. 3 adenosine receptor. Biochem. Pharmacol, 2010, 79(7), 967-973.
164. 3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg. Med. Chem. Lett., 2004, 14(14), 3775-3779. (Pubitemid 38765172)
165. 3 adenosine receptors. Bioorg. Med. Chem., 2003, 11, 347-356. (Pubitemid 36051025)
166. Müller, C. E.; Diekmann, M.; Thorand, M.; Ozola, V. [(3) H]8-Ethyl-4-methyl-2-phenyl-(8R)-4, 5, 7, 8-tetrahydro-1H-imidazo[2, 1-i]-purin-5-one ([(3) H]PSB-11), a novel high-affinity antagonist radioligand for human A (3) adenosine receptors. Bioorg. Med. Chem. Lett., 2002, 12(3), 501-503. (Pubitemid 34113933)
167. 3 adenosine receptor antagonists. J. Med. Chem., 2005, 48, 4910-4918. (Pubitemid 41033133)
168. 3 adenosine receptor antagonists. J. Med. Chem., 1998, 41, 3186-3201. (Pubitemid 28376524)
169. 3 receptor antagonists. Bioorg. Med. Chem., 2004, 12, 613-623. (Pubitemid 38111172)
170. 3 adenosine receptor antagonists. J. Med. Chem., 1997, 40, 2596-2608. (Pubitemid 27347025)
171. 3 adenosine receptors. Bioorg. Med. Chem. Lett. 2000, 10(3), 209-211. (Pubitemid 30105373)
172. Erratum in: Bioorg. Med. Chem. Lett., 2000, 10(12), 1403.
173. Moro, S.; van Rhee, A. M.; Sanders, L. H.; Jacobson, K. A. Flavonoid derivatives as adenosine receptor antagonists: Acomparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. J. Med. Chem., 1998, 41, 46-52. (Pubitemid 28070466)
174. 3 receptor subtype. J. Med. Chem., 1996, 39, 4142-4148. (Pubitemid 26339823)
175. 3 adenosine receptor antagonists. Bioorg. Med. Chem., 2005, 13, 705-715. (Pubitemid 40093613)
176. 3 receptor antagonist. Eur. J. Pharmacol., 2002, 444, 133-141. (Pubitemid 34626830)
177. 3 adenosine receptor antagonist. J. Med. Chem., 2002, 45, 3579-3582. (Pubitemid 34856098)
178. 3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J. Med. Chem., 2002, 45, 4471-4484.
179. 3 receptor antagonist with therapeutic potential. Bioorg. Med. Chem. Lett., 2005, 15, 3081-3085. (Pubitemid 40755200)
180. La Motta, C.; Sartini, S.; Morelli, M.; Taliani, S.; Da Settimo, F. Allosteric modulators for adenosine receptors: An alternative to the orthosteric ligand. Curr. Topics Med. Chem., 2010, 10, 976-992.
181. 1 adenosine receptor. Mini Rev. Med. Chem., 2007, 7, 559-569. (Pubitemid 47099177)
182. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 1-51. (Pubitemid 46277033)
183. Bohr, C.; Hasselbalch, K. A.; Krogh, A. Über einen in biologischer Beziehung wichtigen Einfluss, den die Kohlensäurespannung des Blutes auf dessen Sauerstoffbindung übt. [Concerning a biologically important relationship - the influence of the carbon dioxide content of blood on its oxygen binding]. Skand. Arch. Physiol., 1904, 16, 401-412.
184. Monod, J.; Wyman, J.; Changeux, J.-P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol., 1965, 12, 88-118.
185. Gao, Z.-G.; Kim, S.-K.; IJzerman, A. P.; Jacobson, K. A. Allosteric modulation of the adenosine family of receptors. Mini-Rev. Med. Chem., 2005, 5, 545-553. (Pubitemid 40754168)
186. 1 receptor binding by 2-amino-3- benzoylthiophenes. Mol. Pharmacol., 1990, 38, 950-958.
187. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol., 1990, 38, 939-949.
188. Romagnoli, R.; Baraldi, P. G.; Moorman, A. R.; Iaconinoto, M. A.; Carrion, M. D.; Cara, C. L.; Tabrizi, M. A.; Preti, D.; Fruttarolo, F.; Baker, S. P.; Varani, K.; Borea, P. A. Microwave-assisted synthesis of thieno[2, 3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A1 receptor. Bioorg. Med. Chem., 2006, 16, 5530-5533. (Pubitemid 44415461)
189. 1-adenosine receptor. Bioorg. Med. Chem. Lett., 2000, 10, 1953-1957. (Pubitemid 30663348)
190. 1 receptor: Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J. Med. Chem., 1999, 42, 3629-3635. (Pubitemid 29445096)
191. 1 adenosine receptor. J. Med. Chem., 2003, 46, 794-809. (Pubitemid 36258870)
192. Tranberg, C. E.; Zickgraf, A.; Giunta, B. N.; Luetjens, H.; Figler, H.; Murphree, L. J.; Falke, R.; Fleischer, H.; Linden, J.; Scammells, P. J.; Olsson, R. A. 2-Amino-3-aroyl-4, 5-alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors. J. Med. Chem., 2002, 45, 382-389. (Pubitemid 34073455)
193. Nikolakopoulos, G.; Figler, H.; Linden, J.; Scammels, P. J. 2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. Bioorg. Med. Chem., 2006, 14, 2358-2365. (Pubitemid 43254745)
194. Joshi, E.; Chordia, M. D.; Macdonald, T. J.; Linden, J.; Olsson, R. A. Regioselective oxidation of 2-amino-4, 5-dialkyl-thiophenes. Bioorg. Med. Chem. Lett., 2004, 14, 929-933.
195. Chordia, M. D.; Murphree, L. J.; Macdonald, T. J.; Linden, J.; Olsson, R. A. 2-Aminothiazoles: A new class of agonist allosteric enhancers of adenosine A1 receptors. Bioorg. Med. Chem. Lett., 2002, 12, 1563-1566. (Pubitemid 34569243)
196. Chordia, M. D.; Zigler, M.; Murphree, L. J.; Figler, H.; Macdonald, T. L.; Olsson, R. A.; Linden, J. 6-Aryl-8H-indeno[1, 2-d]thiazol-2-ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency. J. Med. Chem., 2005, 48, 5131-5139. (Pubitemid 41113901)
197. Bueters, T. J. H.; Helden, H. P. M.; Danhof, M.; IJzerman, A. P. Effects of the adenosine A1 receptor allosteric modulators PD 81, 723 and LUF5484 on the striatal acetylcholine release. Eur. J. Pharmacol., 2002, 454, 177-182. (Pubitemid 35287476)
198. Li, X.; Conklin, D.; Ma, W.; Zhu, X.; Eisenach, J. C. Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain. Pain, 2002, 97, 117-125. (Pubitemid 34603315)
199. Li, X.; Conklin, D.; Pan, H.-L.; Eisenach, J. C. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. J. Pharmacol. Exp. Ther., 2003, 305, 950-955. (Pubitemid 36617972)
200. Fawzi, A. B.; Macdonald, D.; Benbow, L. L.; Smith-Torhan, A.; Zhang, H.; Weig, B. C.; Ho, G.; Tulshian, D.; Linder, M. E.; Graziano, M. P. SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol. Pharmacol, 2001, 59, 30-37. (Pubitemid 32043082)
201. Gao, Z.-G.; Gross, A. S.; Jacobson, K. A. Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. Life Sci., 2004, 74, 3173-3180. (Pubitemid 38470108)
202. Göblyös, A.; de Vries, H.; Brussee, J.; IJzerman, A. P. Synthesis and biological evaluation of a new series of 2, 3, 5-substituted [1, 2, 4]-thiadiazoles as modulators of adenosine A1 receptors and their molecular mechanism of action. J. Med. Chem., 2005, 48, 1145-1151. (Pubitemid 40270456)
203. Gao, Z.-G.; IJzerman, A. P. Allosteric modulation of A2a adenosine receptors by amiloride analogues and sodium ions. Biochem. Pharmacol, 2000, 60, 669-676. (Pubitemid 30604249)
204. 3 adenosine receptors. Biochem. Pharmacol, 2003, 65, 525-534. (Pubitemid 36144237)
205. Bruns, R. F.; Lu, G. H. In: Adenosine receptors in the nervous system. Ribeiro, J. A. Ed.; Taylor and Francis. London, 1989, p. 192.
206. Giorgi, I.; Biagi, G.; Bianucci, A. M.; Borghini, A.; Livi, O.; Leonardi, M.; Pietra, D.; Calderone, V.; Martelli, A. N6-1, 3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2a adenosine receptors. Eur. J. Med. Chem., 2008, 43, 1639-1647.
207. 3 adenosine receptors by a series of 3-(2-pyridinyl) isoquinoline derivatives. Mol. Pharmacol, 2001, 60, 1057-1063. (Pubitemid 33027441)
208. van Galen, P. J. M.; Nissen, P.; van Wijngaargen, I.; IJzerman, A. P.; Soudijn, W. 1 H-Imidazo[4, 5-c]quinolin-4-amines: Novel non-xanthine adenosine antagonists. J. Med. Chem., 1991, 34, 1202-1206.
209. 3 adenosine receptors by a series of imidazoquinoline derivatives. Mol. Pharmacol, 2002, 62, 81-89. (Pubitemid 34680519)
210. 3 adenosine receptor. J. Med. Chem., 2006, 49, 3354-3361. (Pubitemid 43830533)
211. 3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol, 2008, 8, 20.
212. 3 adenosine receptor. J. Med. Chem., 2009, 52, 2098-2108.
213. 3 receptor. J. Med. Chem., 2009, 52, 926-931.
214. Szentmiklósi, A. J.; Cseppento, A.; Harmati, G.; Nónósi, P. P. Novel Trends in the Treatment of Cardiovascular Disorders: Site-and Event-Selective Adenosinergic Drugs. Curr. Med. Chem., 2011, Feb. 3.[Epub ahead of print].
215. Al-Awadi, F. M.; Khan, I. Studies on purine enzymes in experimental colitis. Mol. Cell. Biochem., 1999, 194(1-2), 17-22. (Pubitemid 29245538)
216. Al-Awadi, F. M.; Khan, I. Blood purine and energy status in rats with colitis. Dig. Dis. Sci., 2001, 46(2), 443-448. (Pubitemid 32242697)
217. Saven, A.; Piro, L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl. J. Med, 1994, 330, 691-697. (Pubitemid 24066987)
218. Brown, J. B.; Lee, G.; Grimm, G. R.; Barrett, T. A. Therapeutic benefit of Pentostatin in severe IL-10-/-colitis. Inflamm. Bowel Dis., 2008, 14(7), 880-887.
219. Antonioli, L.; Fornai, M.; Colucci, R.; Ghisu, N.; Da Settimo, F.; Natale, G.; Kastsiuchenka, O.; Duranti, E.; Virdis, A.; Vassalle, C.; La Motta, C.; Mugnaini, L.; Breschi, M. C.; Blandizzi, C.; del Tacca, M. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J. Pharmacol. Exp. Therap., 2007, 322, 435-442. (Pubitemid 47105786)
220. 3 receptors. J. Pharmacol. Exp. Ther, 2010, 335(2), 434-442.
221. De Araújo Junqueira, A. F.; Dias, A. A.; Vale, M. L.; Spilborghs, G. M.; Bossa, A. S.; Lima, B. B.; Carvalho, A. F.; Guerrant, R. L.; Ribeiro, R. A.; Brito, G. A. Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice. Infect. Immun., 2011, 79(2), 653-662.
222. Mabley, J. G.; Pacher, P.; Liaudet, L.; Soriano, F. G.; Haskó, G.; Marton, A.; Szabo, C.; Salzman, A. L. Inosine reduces inflammation and improves survival in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver. Physiol, 2003, 284(1), G138-144. (Pubitemid 36076259)
223. Rahimian, R.; Fakhfouri, G.; Daneshmand, A.; Mohammadi, H.; Bahremand, A.; Rasouli, M. R.; Mousavizadeh, K.; Dehpour, A. R. Adenosine A (2A) receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats. Eur. J. Pharmacol, 2010, 649(1-3), 376-381.
224. Pacheco, R.; Martinez-Navio, J. M.; Lejeune, M.; Climent, N.; Oliva, H.; Gatell, J. M.; Gallart, T.; Mallol, J.; Lluis, C.; Franco, R. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc. Natl. Acad. Sci. USA, 2005, 102(27), 9583-9588. (Pubitemid 40981724)
225. 3H] (R)-PIA binding to the caudate nucleus. J. Neurochem., 2008, 107, 161-170.
226. Eigler, A.; Matschke, V.; Hartmann, G.; Erhardt, S.; Boyle, D.; Firestein, G. S.; Endres, S. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor. J. Leukoc. Biol, 2000, 68(1), 97-103.
227. Siegmund, B.; Rieder, F.; Albrich, S.; Wolf, K.; Bidlingmaier, C.; Firestein, G. S.; Boyle, D.; Lehr, H. A.; Loher, F.; Hartmann, G.; Endres, S.; Eigler, A. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J. Pharmacol. Exp. Ther, 2001, 296(1), 99-105. (Pubitemid 32015066)
228. da Silva, C. G.; Jarzyna, R.; Specht, A.; Kaczmarek, E. Extracellular nucleotides and adenosine independently activate AMP-activated protein kinase in endothelial cells: involvement of P2 receptors and adenosine transporters. Circ. Res., 2006, 98(5), e39-47.
229. Salminen, A.; Hyttinen, J. M.; Kaarniranta, K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med, 2011, Mar. 23.
230. Eltzschig, H. K.; Thompson, L. F.; Karhausen, J.; Cotta, R. J.; Ibla, J. C.; Robson, S. C.; Colgan, S. P. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood, 2004, 104(13), 3986-3992. (Pubitemid 39620148)
231. Grünewald, J. K.; Ridley, A. J. CD73 represses pro-inflammatory responses in human endothelial cells. J. Inflamm., 2010, 7(1), 10.
232. Louis, N. A.; Robinson, A. M.; MacManus, C. F.; Karhausen, J.; Scully, M.; Colgan, S. P. Control of IFN-alphaA by CD73: implications for mucosal inflammation. J. Immunol, 2008, 180(6), 4246-4255.
233. 2a receptor agonists activated by ecto-5' - nucleotidase. J. Med. Chem., 2009, 52, 7669-7677.
234. Friedman, D. J.; Künzli, B. M.; A-Rahim, Y. I.; Sevigny, J.; Berberat, P. O.; Enjyoji, K.; Csizmadia, E.; Friess, H.; Robson, S. C. CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl. Acad. Sci. U S A., 2009, 106(39), 16788-16793.
235. Neshat, S.; De Vries, M.; Barajas-Espinosa, A. R.; Skeith, L.; Chisholm, S. P.; Lomax, A. E. Loss of purinergic vascular regulation in the colon during colitis is associated with upregulation of CD39. Am. J. Physiol. Gastrointest. Liver Physiol, 2009, 296, G399-405.
236. van Dieren, J. M.; Kuipers, E. J.; Samsom, J. N.; Nieuwenhuis, E. E.; van der Woude, C. J. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm. Bowel Dis., 2006, 12(4), 311-327.
237. Chan, E. S.; Cronstein, B. N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res., 2002, 4(4), 266-273. (Pubitemid 34716307)
238. Baggott, J. E.; Vaughn, W. H.; Hudson, B. B. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem. J., 1986, 236(1), 193-200. (Pubitemid 16095531)
239. Bai, A.; Ma, A. G.; Yong, M.; Weiss, C. R.; Ma, Y.; Guan, Q.; Bernstein, C. N.; Peng, Z. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem. Pharmacol, 2010, 80(11), 1708-1717.
240. Montesinos, M. C.; Takedachi, M.; Thompson, L. F.; Wilder, T. F.; Fernóndez, P.; Cronstein, B. N. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase genedeficient mice. Arthritis Rheum., 2007, 56(5), 1440-1445. (Pubitemid 46764071)
241. 3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum., 2003, 48(1), 240-247. (Pubitemid 36091669)
242. Riksen, N. P.; Barrera, P.; van den Broek, P. H.; van Riel, P. L.; Smits, P.; Rongen, G. A. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann. Rheum. Dis., 2006, 65(4), 465-470.
243. Gadangi, P.; Longaker, M.; Naime, D.; Levin, R. I.; Recht, P. A.; Montesinos, M. C.; Buckley, M. T.; Carlin, G.; Cronstein, B. N. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol, 1996, 156(5), 1937-1941. (Pubitemid 26069328)
244. Hwang, K. K.; Hall, C. S.; Spielman, W. S.; Sparks, H. V. FK506 promotes adenosine release from endothelial cells via inhibition of adenosine kinase. Eur. J. Pharmacol, 2001, 425(2), 85-93. (Pubitemid 32739153)
245. Spychala, J.; Mitchell, B. S. Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes. J. Lab. Clin. Med., 2002, 140(2), 84-91. (Pubitemid 35028782)
246. Cristalli, G.; Cacciari, B.; Dal Ben, D.; Lambertucci, C.; Moro, S.; Spalluto, G.; Volpini, R. Highlights on the development of A2a adenosine receptor agonists and antagonists. ChemMedChem., 2007, 2, 260-281.
247. 2a adenosine receptor. Identification and characterization of essential amino acid residues. J. Biol Chem., 2010, 285, 13032-13044.
248. 2a receptor antagonists. J. Med. Chem., 2010, 53, 1799-1809.
249. 1 adenosine receptor allosteric modulators and antagonists. Bioorg. Med. Chem., 2009, 17(20), 7353-7361.
250. Kolachala, V.; Asamoah, V.; Wang, L.; Srinivasan, S.; Merlin, D.; Sitaraman, S. V. Interferon-γ down-regulates adenosine 2b receptor-mediated signaling and short circuit current in the intestinal epithelia by inhibiting the expression of adenylate cyclase. J. Biol Chem., 2005, 280(6), 4048-4057. (Pubitemid 40288568)
251. 2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J. Immunol, 1999, 162(6), 3607-3614. (Pubitemid 29313615)
252. Khoa, N. D.; Montesinos, M. C.; Reiss, A. B.; Delano, D.; Awadallah, N.; Cronstein, B. N. Inflammatory cytokines regulate function and expression of adenosine A (2A) receptors in human monocytic THP-1 cells. J. Immunol, 2001, 167(7), 4026-4032. (Pubitemid 32910848)
253. Khoa, N. D.; Montesinos, M. C.; Williams, A. J.; Kelly, M.; Cronstein, B. N. Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells. J. Immunol, 2003, 171(8), 3991-3998. (Pubitemid 37238673)
254. Kiss, J.; Yegutkin, G. G.; Koskinen, K.; Savunen, T.; Jalkanen, S.; Salmi, M. IFN-beta protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol, 2007, 37(12), 3334-3338.
255. Ji, X.; Melman, N.; Jacobson, K. A. Interactions of flavonoids and other phytochemicals with adenosine receptors. J. Med. Chem., 1996, 39, 781-788. (Pubitemid 26069697)
256. Müller, C. E. A1 adenosine receptors and their ligands: overview and recent developments. Il Farmaco, 2000, 56, 77-80.
257. 3 receptor pharmacology by the food dye Brilliant Black BN: Evidence for allosteric interactions. Mol Pharmacol, 2010, 77, 678-686.
258. 3 adenosine receptor. Biochem. Pharmacol, 2010, 79, 48-56.
259. Schumacher, A.; Scholle, S.; Hölzl, J.; Khudeir, N.; Hess, S.; Müller, C. E. Lignans isolated from Valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors. J. Nat. Prod., 2002, 65, 1479-1485. (Pubitemid 35239637)
260. Bäckhed, F.; Ley, R. E.; Sonnenburg, J. L.; Peterson, D. A.; Gordon, J. I. Hostbacterial mutualism in the human intestine. Science, 2005, 307(5717), 1915-1920.
261. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K. S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; Mende, D. R.; Li, J.; Xu, J.; Li, S.; Li, D.; Cao, J.; Wang, B.; Liang, H.; Zheng, H.; Xie, Y.; Tap, J.; Lepage, P.; Bertalan, M.; Batto, J. M.; Hansen, T.; Le Paslier, D.; Linneberg, A.; Nielsen, H. B.; Pelletier, E.; Renault, P.; Sicheritz-Ponten, T.; Turner, K.; Zhu, H.; Yu, C.; Li, S.; Jian, M.; Zhou, Y.; Li, Y.; Zhang, X.; Li, S.; Qin, N.; Yang, H.; Wang, J.; Brunak, S.; Doré, J.; Guarner, F.; Kristiansen, K.; Pedersen, O.; Parkhill, J.; Weissenbach, J.; MetaHIT Consortium; Bork, P.; Ehrlich, S. D.; Wang, J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 2010, 464(7285), 59-65.
262. Gill, S. R.; Pop, M.; Deboy, R. T.; Eckburg, P. B.; Turnbaugh, P. J.; Samuel, B. S.; Gordon, J. I.; Relman, D. A.; Fraser-Liggett, C. M.; Nelson, K. E. Metagenomic analysis of the human distal gut microbiome. Science, 2006, 312(5778), 1355-1359. (Pubitemid 43839542)
263. Fujimura, K. E.; Slusher, N. A.; Cabana, M. D.; Lynch, S. V. Role of the gut microbiota in defining human health. Expert Rev. Anti Infect. Ther., 2010, 8(4), 435-454.
264. Tannock, G. W. The bowel microbiota and inflammatory bowel diseases. Int. J. Inflam., 2010, 2010. 954051.
265. 2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacterinduced gastritis and bacterial persistence. Mucosal Immunol., 2009, 2(3), 232-242.
266. Alam, M. S.; Kurtz, C. C.; Rowlett, R. M.; Reuter, B. K.; Wiznerowicz, E.; Das, S.; Linden, J.; Crowe, S. E.; Ernst, P. B. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J. Infect. Dis., 2009, 199(4), 494-504.
267. 2B receptors. PLoS One., 2009, 4(12), e8299.
268. Walia, B.; Castaneda, F. E.; Wang, L.; Kolachala, V. L.; Bajaj, R.; Roman, J.; Merlin, D.; Gewirtz, A. T.; Sitaraman, S. V. Polarized fibronectin secretion induced by adenosine regulates bacterial-epithelial interaction in human intestinal epithelial cells. Biochem. J., 2004, 382, 589-596. (Pubitemid 39243926)
269. Strohmeier, G. R.; Lencer, W. I.; Patapoff, T. W.; Thompson, L. F.; Carlson, S. L.; Moe, S. J.; Carnes, D. K.; Mrsny, R. J.; Madara, J. L. Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J. Clin. Invest., 1997, 99(11), 2588-2601. (Pubitemid 27259805)
270. Borenshtein, D.; Fry, R. C.; Groff, E. B.; Nambiar, P. R.; Carey, V. J.; Fox, J. G.; Schauer, D. B. Diarrhea as a cause of mortality in a mouse model of infectious colitis. Genome Biol., 2008, 9(8), R122.
271. Crane, J. K.; Olson, R. A.; Jones, H. M.; Duffey, M. E. Release of AT P during host cell killing by enteropathogenic E. coli and its role as a secretory mediator. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 283(1), G74-86. (Pubitemid 34666165)
272. Crane, J. K.; Shulgina, I.; Naeher, T. M. Ecto-5'-nucleotidase and intestinal ion secretion by enteropathogenic Escherichia coli. Purinergic Signal., 2007, 3(3), 233-246.
273. Crane, J. K.; Shulgina, I. Feedback effects of host-derived adenosine on enteropathogenic Escherichia coli. FEMS Immunol. Med. Microbiol., 2009, 57, 214-228.
274. Greenwell-Wild, T.; Vózquez, N.; Sim, D.; Schito, M.; Chatterjee, D.; Orenstein, J. M.; Wahl, S. M. Mycobacterium avium infection and modulation of human macrophage gene expression. J. Immunol., 2002, 169(11), 6286-6297. (Pubitemid 36903476)
275. Thammavongsa, V.; Kern, J. W.; Missiakas, D. M.; Schneewind, O. Staphylococcus aureus synthesizes adenosine to escape host immune responses. J. Exp. Med., 2009, 206(11), 2417-2427.
276. Estrela, A. B.; Gutierrez, M.; Abraham, W.-R. In: GutMicroEcology, Proceedings of the International Scientific Conference on Gastro-Intestinal Microbial Ecology, Kosice, Slovak Republic, November 9-11, 2010; PAMIDA international Ltd.: Kysucke Nove Mesto, SK, 2010; pp. 14-15.
277. Aldhous, M. C.; Noble, C. L.; Satsangi, J. Dysregulation of human betadefensin-2 protein in inflammatory bowel disease. PLoS One, 2009, 4(7), e6285.
278. Wehkamp, J.; Fellermann, K.; Herrlinger, K. R.; Baxmann, S.; Schmidt, K.; Schwind, B.; Duchrow, M.; Wohlschläger, C.; Feller, A. C.; Stange, E. F. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol., 2002, 14(7), 745-752. (Pubitemid 34753958)
279. Hörmannsperger, G.; Haller, D. Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease. Int J Med Microbiol., 2010, 300(1), 63-73.
280. Wehkamp, J.; Harder, J.; Wehkamp, K.; Wehkamp-von Meissner, B.; Schlee, M.; Enders, C.; Sonnenborn, U.; Nuding, S.; Bengmark, S.; Fellermann, K.; Schröder, J. M.; Stange, E. F. NF-kappaB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun., 2004, 72(10), 5750-5758. (Pubitemid 39303685)
281. Möndel, M.; Schroeder, B. O.; Zimmermann, K.; Huber, H.; Nuding, S.; Beisner, J.; Fellermann, K.; Stange, E. F.; Wehkamp, J. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol., 2009, 2(2), 166-172.
282. Antonioli, L.; Fornai, M.; Colucci, R.; Ghisu, N.; Tuccori, M.; Del Tacca, M.; Blandizzi, C. Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases. Inflamm. Bowel Dis., 2008, 14(4), 566-574. (Pubitemid 351571838)
283. Ye, J. H.; Rajendran, V. M. Adenosine: an immune modulator of inflammatory bowel diseases. World J. Gastroenterol., 2009, 15(36), 4491-4498.
284. Rybaczyk, L.; Rozmiarek, A.; Circle, K.; Grants, I.; Needleman, B.; Wunderlich, J. E.; Huang, K.; Christofi, F. L. New bioinformatics approach to analyze gene expressions and signaling pathways reveals unique purine gene dysregulation profiles that distinguish between CD and UC. Inflamm. Bowel Dis., 2009, 15(7), 971-984.